2006
DOI: 10.1016/j.canlet.2005.04.016
|View full text |Cite
|
Sign up to set email alerts
|

Ursodeoxycholic acid differentially affects three types of sphingomyelinase in human colon cancer Caco 2 cells

Abstract: AbstractsWe investigated the effects of UDCA on sphingomyelinase (SMase) in Caco 2 cells cultured under monolayer and polarized conditions. Alkaline SMase activity was high in polarized cells whereas acid and neutral SMase activities were high in monolayer cells. In polarized cells UDCA increased alkaline SMase expression and caspase 3 activity but had no effect on acid and neutral SMases. In monolayer cells, UDCA reduced both acid and neutral SMase activities, inhibited cell proliferation, but had little effe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
18
0

Year Published

2007
2007
2018
2018

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 27 publications
(19 citation statements)
references
References 22 publications
1
18
0
Order By: Relevance
“…It is well-known that PSC increases the risk of hepatobiliary cancer (Yang et al, 2001;Ohata et al, 2003;Lazaridis and Gores, 2006) as well as colon cancer associated with colitis (Broome and Bergquist, 2006). The disease is treated with ursodeoxycholic acid to decrease the risk of colorectal cancer (Pardi et al, 2003) and ursodeoxycholic acid has been shown to induce expression alk-SMase in both animal models and cell culture studies (Cheng et al, 1999;Liu et al, 2006). We therefore raised a question whether this ectoenzyme may also be an antitumour factor both in development of primary hepatic and biliary carcinomas and in the regulation of metastatic tumour growth.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It is well-known that PSC increases the risk of hepatobiliary cancer (Yang et al, 2001;Ohata et al, 2003;Lazaridis and Gores, 2006) as well as colon cancer associated with colitis (Broome and Bergquist, 2006). The disease is treated with ursodeoxycholic acid to decrease the risk of colorectal cancer (Pardi et al, 2003) and ursodeoxycholic acid has been shown to induce expression alk-SMase in both animal models and cell culture studies (Cheng et al, 1999;Liu et al, 2006). We therefore raised a question whether this ectoenzyme may also be an antitumour factor both in development of primary hepatic and biliary carcinomas and in the regulation of metastatic tumour growth.…”
Section: Discussionmentioning
confidence: 99%
“…Determination of SMase, galactosidase and proteins The activities of acid, neutral and alk-SMase were determined as described, using choline-labelled SM ([ 14 C-SM]) as substrate in different assay buffers (Duan and Nilsson, 2000;Liu et al, 2006). The activity of b-galactosidase in COS-7 cells after transfection was assayed by a b-gal assay kit (Invitrogen), using ortho-nitrophenyl-b-galactopyranoside as substrate (Wu et al, 2004a).…”
Section: Methodsmentioning
confidence: 99%
“…Ceramide can be generated either by de novo synthesis via activation of ceramide synthase or by sphingomyelin hydrolysis, following activation of acid, neutral or alkaline sphingomyelinases [6,7]. Although recent studies also involve neutral or alkaline sphingomyelinase in the induction of apoptosis [8,9], most studies investigated the role of acid sphingomyelinase-released ceramide in cell death. Ceramide has been shown to play a significant role in signalling triggered by both intrinsic and extrinsic apoptosis-inducing stimuli, which suggests that the mechanisms of ceramide-mediated cell death are complex and diverse.…”
Section: Introductionmentioning
confidence: 99%
“…Third, the expression of Alk-SMase can be induced by ursodeoxycholic acid both in rats [16] and in a human colon cancer derived cell line [17]. The effect is more potent on differentiated enterocytes than on proliferating cells.…”
Section: Introductionmentioning
confidence: 99%